Skip to content

BAMF Health Clinical Trials

BAMF Health’s patients have the opportunity to participate in the most advanced clinical trials available for cancer patients. Please select the option below that is most appropriate to your individual needs and follow the link to our intake form.

Our clinical team of Theranostics experts will review your responses and return your call within 48 hours.

Current Clinical Trials

BAMF Health is currently conducting the following advanced clinical trials for prostate cancer

ECLIPSE Trial A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

Protocol Title: A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

Short Name: ECLIPSE Trial

Sponsor: Curium

Description: This is a prospective, open-label, multi-center, randomized, Phase 3 study evaluating Lutetium 177Lu-PSMA-I&T as treatment compared to standard of care hormone therapy in men with metastatic Castration-Resistant Prostate Cancer.

The study will include a total of 400 patients with metastatic prostate cancer and documented positive PSMA PET imaging. Patients will be randomized at a ratio of 2:1 to receive either 177Lu-PSMA-I&T or hormone therapy (abiraterone or enzalutamide) respectively. Patients randomized to the investigational product will receive up to 4 treatments every 6 weeks at a dose of 200 mCi (7.4 GBq). All patients will be followed for adverse events and safety labs throughout the course of the study. Progression of disease will be assessed radiographically using Prostate Working Group Criteria 3 (PWGC3) and Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of conventional imaging as well as PSA levels and symptom recording throughout the course of treatment.

30 patients will participate in a pharmacokinetic and radiation dosimetry sub-study at selected participating clinical sites. Sub-study participants will receive SPECT imaging after each treatment cycle for dosimetry analysis. Sub-study participants will not be randomized.

Patient Enrollment at BAMF: September 12, 2022

Number of patients to be enrolled (study wide): 400

Number of clinical sites in the US: 25 at present

Patient Eligibility Criteria: please click here to see the complete list

To get more information or be connected to discuss this clinical trial with someone at BAMF Health, please complete this form

SABRE Trial A Phase II Positron Emission Tomography (PET) imaging trial of participants with PSMA-negative biochemical recurrence (BCR) of prostate cancer following definitive therapy.

Protocol Title: 64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)

Short Name: SABRE Trial

Sponsor: Clarity

Description: The aim of this study is to determine the safety and efficacy of 64Cu-SAR-BBN and determine the ability of 64Cu-SAR-BBN Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate cancer in participants with PSMA-negative biochemical recurrence of prostate cancer following definitive therapy.

Patient Enrollment at BAMF: January 12, 2023

Number of patients to be enrolled (study wide): 50

Number of clinical sites in the US: 8 at present

Patient Eligibility Criteria: please click here to see the complete list

To get more information or be connected to discuss this clinical trial with someone at BAMF Health, please complete this form

Pancreatic Cancer Imaging Study

Protocol Title: Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma (FAPI-46 PDAC)

Sponsor: SOFIE Biosciences

Description: This is a prospective, multi-center, single arm, open label, non-randomized study to evaluate the ability of [68Ga]FAPI-46 to detect FAP expressing cells in patients with resectable or borderline resectable PDAC. The [68Ga]FAPI-46 PET scans will be acquired after initial staging using institutional standard methods. If the participant is prescribed neoadjuvant therapy, a second [68Ga]FAPI-46 PET scan will be performed within 21 days prior to planned surgical resection. This will be followed by histopathology and IHC analyses and comparison to resected PDAC tumor specimens.

Patient Enrollment at BAMF: Estimated for June 1, 2023

Number of patients to be enrolled (study wide): 60

Number of clinical sites in the US: 4 at present

Patient Eligibility Criteria:  please click here to see the complete list (https://clinicaltrials.gov/ct2/show/NCT05262855)

To get more information or be connected to discuss this clinical trial with someone at BAMF Health, please complete this form

Future Clinical Trials

BAMF Health will soon begin to host clinical trials for many forms of cancer and disease states. To participate in the BAMF Health Clinical Trial Platform, your physician must refer you to our team.

Please fill out this form so that our team may alert you when a trial opens for your type of cancer or disease